EA200702419A1 - NEW CONNECTIONS AS GLP-1 AGONISTS - Google Patents

NEW CONNECTIONS AS GLP-1 AGONISTS

Info

Publication number
EA200702419A1
EA200702419A1 EA200702419A EA200702419A EA200702419A1 EA 200702419 A1 EA200702419 A1 EA 200702419A1 EA 200702419 A EA200702419 A EA 200702419A EA 200702419 A EA200702419 A EA 200702419A EA 200702419 A1 EA200702419 A1 EA 200702419A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glp
agonists
new connections
connections
new
Prior art date
Application number
EA200702419A
Other languages
Russian (ru)
Inventor
Брадж Бхушан Лохрай
Видья Бхушан Лохрай
Раджеш Х. Бахекар
Original Assignee
Кадила Хелзкэр Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кадила Хелзкэр Лимитед filed Critical Кадила Хелзкэр Лимитед
Publication of EA200702419A1 publication Critical patent/EA200702419A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение описывает группу новых пептидомиметиков, которые можно использовать для лечения диабета. Данные соединения определяются общей формулой (I), приведенной ниже.A-X-S-Y-S-X-B (I)The present invention describes a group of novel peptidomimetics that can be used to treat diabetes. These compounds are defined by general formula (I) below. A-X-S-Y-S-X-B (I)

EA200702419A 2005-05-05 2006-05-04 NEW CONNECTIONS AS GLP-1 AGONISTS EA200702419A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN558MU2005 2005-05-05
IN645MU2005 2005-05-31
PCT/IN2006/000154 WO2007017892A2 (en) 2005-05-05 2006-05-04 Novel compounds as glp-i agonists

Publications (1)

Publication Number Publication Date
EA200702419A1 true EA200702419A1 (en) 2008-04-28

Family

ID=37727716

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702419A EA200702419A1 (en) 2005-05-05 2006-05-04 NEW CONNECTIONS AS GLP-1 AGONISTS

Country Status (12)

Country Link
EP (1) EP1891106A2 (en)
JP (1) JP2008540402A (en)
KR (1) KR20080021636A (en)
AP (1) AP2007004227A0 (en)
AU (1) AU2006277557A1 (en)
BR (1) BRPI0612471A2 (en)
CA (1) CA2606894A1 (en)
EA (1) EA200702419A1 (en)
IL (1) IL187105A0 (en)
MX (1) MX2007013655A (en)
NO (1) NO20075618L (en)
WO (1) WO2007017892A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
DK2084182T3 (en) * 2006-10-03 2013-11-04 Cadila Healthcare Ltd ANTIDIABETIC RELATIONS
CA2707132A1 (en) * 2007-12-11 2009-06-18 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
CA2707448C (en) 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
CA2759468A1 (en) * 2009-05-01 2010-11-04 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
CN101891823B (en) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 Exendin-4 and analog fusion protein thereof
EP2956160B1 (en) * 2013-02-15 2018-04-25 Mayo Foundation For Medical Education And Research Insulin secreting polypeptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
GB0024428D0 (en) * 2000-10-05 2000-11-22 King S College Absorption enhancers
DE60228972D1 (en) * 2001-07-31 2008-10-30 Us Gov Health & Human Serv GLP 1 EXENDIN 4 PEPTIDE ANALOG AND THEIR USES
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
BR0306706A (en) * 2002-01-08 2007-03-27 Lilly Co Eli glp-1 peptide extended, methods of glp-1 receptor stimulation in an individual requiring blood glucose normalization, treatment of an individual prophylactically for insulin-independent diabetes, reduction or maintenance of body weight, treatment of obesity , and treatment of diseases, in an individual in need thereof, use of a glp-1 compound, process of preparing a pharmaceutical formulation, and, pharmaceutical formulation.
WO2005077072A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
DE102004043153B4 (en) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Invention relating to GLP-1 and exendin

Also Published As

Publication number Publication date
AP2007004227A0 (en) 2007-12-31
IL187105A0 (en) 2008-02-09
KR20080021636A (en) 2008-03-07
BRPI0612471A2 (en) 2016-09-06
MX2007013655A (en) 2008-01-24
CA2606894A1 (en) 2007-02-15
WO2007017892A2 (en) 2007-02-15
AU2006277557A1 (en) 2007-02-15
NO20075618L (en) 2008-01-30
WO2007017892A3 (en) 2007-09-20
EP1891106A2 (en) 2008-02-27
JP2008540402A (en) 2008-11-20

Similar Documents

Publication Publication Date Title
CY1119515T1 (en) OXAZOL Substituted Indazoles as R3-Kinase Suspensions
BRPI0615705A2 (en) process for preparing a compound and compound
EA200702419A1 (en) NEW CONNECTIONS AS GLP-1 AGONISTS
EA201100875A1 (en) NEW PYRAZOL-4-N-ALKOXYCARBOXAMIDES AS MICROBIOCIDES
UA107791C2 (en) Pesticidal compositions
EA201071032A1 (en) Heterocyclic Compound
CY1109911T1 (en) PYRROLOVENZODIAZEPINES
BRPI0812222A2 (en) CYCLOBUTENTION COMPOUNDS REPLACED ANTI-INFLAMMATORY.
EA201070039A1 (en) SPIROCYCLES AS AN INHIBITORS 11-BETA HYDROXYL-STEROID DEHYDROGENASE TYPE 1
MY153915A (en) Organic compounds
EA200601295A1 (en) 1,3-DIOXANE DERIVATIVES AND THEIR ANALOGUES APPLICABLE FOR THE TREATMENT I.A. OBESITY AND DIABETES
UA116809C2 (en) APPLICATION OF AGROCHEMICAL MIXTURES FOR INCREASING THE VITALITY OF THE PLANT
ATE417849T1 (en) PYRAZOLOA4,3-DÜPYRIMIDINE
MA32505B1 (en) 5-alkynyl-PYRIMIDINE
EA201170132A1 (en) 5-HETEROCYCLILALKYL-3-HYDROXY-2-PHENYLCYCLOPENT-2-UNONES AS HERBICIDES
EA201170168A1 (en) COMPLEX (MINERAL-AMINO ACID) - POLYSACCHARIDE
BRPI0816911A8 (en) PROCESS FOR PREPARATION OF 4-AMINOBUT-2-ENOLIDES
EA201101099A1 (en) HERBICIDES OBTAINED FROM CYCLOPENTADION
NI200900151A (en) NEW PROCEDURE FOR THE SYNTHESIS OF AGOMELATIN.
UY30371A1 (en) CHEMICAL COMPOUNDS
DE602006009789D1 (en) acetylene
UA106880C2 (en) NEW HERBICIDES
CU20100099A7 (en) 5 - [(3,3,3-TRIFLUORO-2-HIDROXI-1-ARILPROPIL) AMINO] -1H-QUINOLIN-2-ONAS, A PROCESS FOR ITS PRODUCTION AND ITS USE AS ANTINFLAMATORY AGENTS
NO20081207L (en) Isoquinolines as IGF-1R Inhibitors
EA200801549A1 (en) NEW PENANTRIDINE DERIVATIVES AS ANTAGONISTS OF BRADIKININ